NOVEL REGIMEN FOR CONTROLLED OVARIAN STIMULATION IN MACAQUES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 重组人促性腺激素（例如，促卵泡激素（FSH）通常用于促进非人灵长类动物和妇女的辅助生殖技术中的卵泡发育。由于它们在体内的半衰期相对较短，可用的制剂作为每日肌内或皮下注射给药，通常间隔8-14天，这可能与患者不适、局部刺激和女性依从性降低有关。 重组人促性腺激素对非人灵长类动物不育研究具有重要意义，它最终会导致中和抗体的产生，从而妨碍进一步的刺激方案和有效利用宝贵的动物资源。 目前促性腺激素治疗不孕妇女的卵泡刺激或排卵诱导的发展集中在产生体内半衰期更长的重组促性腺激素或促性腺激素模拟物。 因此，正在进行临床前研究，以测试一种新型促性腺激素在非人灵长类动物模型中刺激卵泡的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant human gonadotropins (e.g., follicle stimulating hormone, FSH) are routinely used to promote follicular development for assisted reproductive technologies in nonhuman primates and women. Because of their relatively short half-life in vivo, the available preparations are administered as daily intramuscular or subcutaneous injections, often for 8-14 day intervals, which can be associated with patient discomfort, local irritation and decreased compliance in women. Of importance to nonhuman primate infertility research, recombinant human gonadotropins elicit eventual production of neutralizing antibodies that precludes further stimulation protocols and efficient use of a valuable animal resource. Current developments in gonadotropin therapy for follicular stimulation or ovulation induction in infertile women focus on creating recombinant gonadotropins with longer half-lives in vivo, or gonadotropin mimetics. Therefore, a pre-clinical study is underway to test the efficacy of a novel gonadotropin for follicular stimulation in a nonhuman primate model.